Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | 23814 + Tivozanib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
23814 | NOTCH1 Antibody 2 | 23814 is a monoclonal antibody that binds to the Notch1 ligand-binding domain and inhibits ligand-mediated signaling, potentially resulting in decreased tumor growth (PMID: 25995436). | ||
Tivozanib | AV-951|AV951|KIL-8951|KRN 951|KRN-951 | VEGFR Inhibitor (Pan) 32 | Tivozanib (AV-951) inhibits VEGFR1-3, which may result in decreased tumor angiogenesis and proliferation and increased cell death (PMID: 23788831, PMID: 31810797, PMID: 32547647). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | fibrosarcoma | not applicable | 23814 + Tivozanib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with the combination of 23814 and Tivozanib (AV-951) resulted in tumor growth inhibition in a fibrosarcoma cell line xenograft model, with increased efficacy over either agent alone (PMID: 25995436). | 25995436 |
ERBB2 V659E | breast cancer | sensitive | 23814 + Tivozanib | Preclinical | Actionable | In a preclinical study, the combination of 23814 and Tivozanib (AV-951) inhibited tumor growth in several transgenic mouse models of breast cancer expressing ERBB2 (HER2) V659E, including those with resistance to VEGFR inhibitors (PMID: 25995436). | 25995436 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|